Literature DB >> 19867385

The c3-activator system: an alternate pathway of complement activation.

O Götze1, H J Müller-Eberhard.   

Abstract

Evidence has accumulated indicating the existence of a second complement activation mechanism which is functionally analogous to C1, C2, and C4. The noncomplement protein C3PA, previously recognized through its ability to form a complex enzyme with a protein from cobra venom, appears to be the precursor of the C4,2 analogue. It is a thermolabile beta-globulin with a molecular weight of 80,000. When serum is treated with naturally occurring plant or bacterial polysaccharides, the C3PA is cleaved into at least two fragments, one having the electrophoretic mobility of a gamma-globulin and a molecular weight of 60,000, and the other being an acidic peptide with a molecular weight of 20,000. The larger fragment has the ability to cleave C3 into C3a and C3b and is therefore called C3 activator. It arises from the action of an as yet unidentified serum enzyme upon the C3PA, which is tentatively called C3PA convertase. In addition to endotoxins, yeast cell walls, inulin, and agar, aggregates of immunoglobulins were found to be activating substances, including human IgA, guinea pig gamma1, and duck antibody. Serum depleted of C3PA had reduced E. coli bactericidal and increased hemolytic activity. The relationship of the C3-activator system to experimental and clinical observations has been discussed.

Entities:  

Year:  1971        PMID: 19867385      PMCID: PMC2139059     

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  Alternative complement pathway: activity levels in allogeneic pregnancy.

Authors:  M Brai; G Tolone; A Magro; H Waks; M Brai
Journal:  Experientia       Date:  1976-12-15

2.  An anti-inflammatory substance in normal human plasma.

Authors:  M J Smith; A W Ford-Hutchinson
Journal:  Agents Actions       Date:  1975-10

3.  The Bf locus in the HLA region of chromosome 6: linkage and association studies.

Authors:  B Olaisen; P Teisberg; T Gedde-Dahl; E Thorsby
Journal:  Humangenetik       Date:  1975-12-23

4.  IgA-nephropathy (IgA-IgG-nephropathy/IgA-nephritis)--a disease entity?

Authors:  H V Gärtner; F Hönlein; U Traub; A Bohle
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979-12

Review 5.  Genetic loci of components of the classical and alternate pathway of complement activation: a new dimension of the immunogenetic linkage group (HLA) on chromosome 6 in man.

Authors:  C Rittner
Journal:  Hum Genet       Date:  1976-12-29       Impact factor: 4.132

6.  Intestinal IgA deposition in Henoch-Schönlein purpura with severe gastro-intestinal manifestations.

Authors:  S Kato; K Ebina; H Naganuma; S Sato; S Maisawa; H Nakagawa
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

7.  Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.

Authors:  Jitendra Kumar; Viveka Nand Yadav; Swastik Phulera; Ashish Kamble; Avneesh Kumar Gautam; Hemendra Singh Panwar; Arvind Sahu
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

8.  Activation of the alternative and classical complement pathways by Entamoeba histolytica.

Authors:  J Calderon; R D Schreiber
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

9.  IgA glomerulonephritis. Mesangial IgA deposition without systemic signs (Berger's disease).

Authors:  J Nagy; H Brasch; T Süle; A Hámori; G Deák; M Ambrus
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

10.  Properdin factor B-polymorphism. An indication for the existence of a Bf O-allele.

Authors:  S Weidinger; F Schwarzfischer; H Cleve
Journal:  Z Rechtsmed       Date:  1979-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.